Long non-coding RNA p53 upregulated regulator of p53 levels (PURPL) promotes the development of gastric cancer

Abstract

Gastric cancer (GC), one of the most prevalent malignancies across the world, has an increasing incidence rate. Long non-coding RNA (lncRNA) PURPL (also referred to as LINC01021) has been demonstrated to influence malignant GC behaviors and partake in other cancers. Notwithstanding, reports pertaining to the underlying mechanism of PURPL in GC haven’t been rarely seen. Presently, in-vivo and ex-vivo experiments were implemented to examine the PURPL-miR-137-ZBTB7A-PI3K-AKT-NF-κB regulatory axis in GC. Our statistics revealed that PURPL presented a high expression in GC tissues and cell lines. PURPL overexpression remarkably exacerbated colony formation, migration, and invasion and repressed apoptosis in GC cells (AGS and MNK-45). In-vivo experiments also corroborated that cell growth was boosted by PURPL up-regulation. Mechanistic investigations verified that PURPL interacted with miR-137 and lowered its profile in GC cell lines. miR-137 overexpression or ZBTB7A knockdown upended the oncogenic function mediated by PURPL. PURPL initiated the PI3K/AKT/NF-κB pathway. PI3K and NF-κB inhibition impaired the promoting impact on GC cells elicited by PURPL overexpression and contributed to PURPL down-regulation. These findings disclosed that PURPL serves as an oncogene in the context of GC via miR-137-ZBTB7A-PI3K-AKT-NF-κB axis modulation.

A comparative analysis of transcriptomics of newly diagnosed multiple myeloma: exploring drug repurposing

“…Interestingly, the 3 long non-coding RNA molecules were expressed by a large percentage of patients (88%, 85%, 83% respectively) whereas the expression of PURPL and LINC01239 was almost absent in healthy donors. Mechanistically, of the 3 non-coding RNA genes, PURPL is the only one that has been thoroughly studied and is implicated in the pathogenesis of several solid malignancies by interfering with crucial signaling cascades and pathways ( 40 , 63 – 66 ).…”

Transcriptomics analysis of long non-coding RNAs in smooth muscle cells from patients with peripheral artery disease and diabetes mellitus

“…Some of them, for instance, ENSG00000289474, with a 12-fold reduction in its expression in PAD patients with DM, might be of interest to be further investigated. Many of the remaining lncRNAs, such as LINC01220, CYTOR, LINC00910, LINC00511, PURPL, and MZF1-AS1, have been described in association with different types of cancer 30 – 35 . Interestingly, the expression changes were associated mainly with cell proliferation and migration of the tumour cells.…”

Machine learning predicts metastatic progression using novel differentially expressed lncRNAs as potential markers in pancreatic cancer

“…All of which lacking studies in PC. Nonetheless, LINC02575 has been found to be implicated in proliferation of laryngeal squamous cell carcinomas 70 ; PURPL was indicated to have an involvement in ovarian and gastric cancers 71–73 ; and AL035425.3 was suggested to be implicated in the prognosis of triple negative breast cancer 74 .…”